PT Kalbe Farma Tbk. (PTKFY) Research

Established in Jakarta, Indonesia, in 1966, PT Kalbe Farma Tbk. and its subsidiaries specialize in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products across Indonesia. The company's operations are strategically organized into four key divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution & Logistics. Their offerings encompass a comprehensive range of generic, branded, and licensed prescription medications—including well-known names like Brainact, Cefspan, and Neuralgin—which are supplied to hospitals, pharmacies, and drugstores nationwide. Beyond prescription drugs, Kalbe Farma provides an array of over-the-counter medicines, energy beverages, ready-to-drink options, dietary supplements, and other preventive health solutions. Their nutritional product line serves a broad demographic, from infants and toddlers to children, teenagers, adults, pregnant and lactating women, and the elderly, as well as individuals with specialized medical needs. Furthermore, the company extends its services to pharmaceutical firms through contract research, including clinical study management, bioavailability/bioequivalence assessments, and analytical testing. Kalbe Farma also contributes to animal health, operates the Mitrasana Clinics for healthcare services, and offers health screening. Its extensive activities also involve acting as an agent and representative for biotechnology products, distributing consumer goods, medical devices, and cosmetics, and engaging in the trade of medical and laboratory equipment, pharmaceutical raw materials, and hemodialysis consumables. Additionally, they provide advertising services.

Open PT Kalbe Farma Tbk. (PTKFY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.